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While vigabatrin-associated visual fiel constrictions have been generally considered irreversible, some case reports have raised
the hope of partial improvement after drug withdrawal in occasional patients. Here we describe seven children with epilepsy,
whose visual fiel constrictions, as demonstrated by the kinetic perimetry (Goldmann), attenuated or recovered after discontin-
uation of vigabatrin therapy. While this improvement may be largely due to better performance in later test sessions, we want
to raise the possibility that some visual fiel recovery may be possible at least in young patients.
c© 2001 BEA Trading Ltd
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INTRODUCTION
Several hundred cases of bilateral visual fiel constric-
tions (VFC) have been reported in association with vi-
gabatrin (VGB) therapy1, 2. Studies on adult patients
on VGB therapy have shown that up to 40 percent
of the patients may develop VFC, most of them are
asymptomatic, and all are generally considered irre-
versible. While some characteristics of VFC in adults
have been identified there is very little data on the
paediatric VGB-treated patients. Up until now only a
few reports have appeared, and they suggest that VFC
may also occur in children3–6. However, there are nu-
merous difficultie in testing visual field in children:
intelligence or young age may not allow for reliable
collaboration, and children show a visual fiel learn-
ing effect, i.e. a marked improvement in repeated test
sessions. Therefore the range in reference values for
the extents of visual field in normal children is wide
and age dependent7, and detection of slight changes in
visual field may be difficult
Recently, occasional adult8, 9 and paediatric5, 10, 11
patients have been reported to show slight reversal
or improvement of VFC after discontinuation of their
VGB therapy. These reports have raised a hope of re-
covery of VFC in some patients. However, up until
now there has only been single case reports of one to
two patients showing recovery, which is not sufficien
for reasonable clinical decision making. The earliest
report of improvement in a child patient10 was later
suspected to result from an artefact of the learning ef-
fect8. Due to the difficultie in testing children12 the
question occurs as to whether there is a true reversal
of the retinal defect or whether improvement relates
to better collaboration and/or concentration during the
testing session. Here we report seven young patients
whose visual fiel defects recovered after cessation of
their vigabatrin therapy. Visual field were assessed by
Goldmann’s kinetic perimetry, and VGB therapy was
discontinued because of reductions in visual field or
lack of effica y.
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Fig. 1: These figures show the changes in the Goldmann perimetry in patient #4. The duration of the vigabatrin therapy at each
test session is indicated. Outer limit (black line) has been obtained with the stimulus IV/4 and the inner limit (grey line) with the
stimulus I/2. Note that the transient constriction was observed in both isopters.
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Table 1: Clinical details of the patients showing improvement in the kinetic Goldmann perimetry.
Patient Other Duration of Total dose of Worst visual fiel Latest visual fiel
No./Age antiepileptic VGB therapy VGB (grams) (degrees; temp/nasal) (degrees; temp/nasal) Stimulus
(yr.)/sex medication (months) (months after VGB withdrawal)
#1/10/m VPA,OXC 21 1024 70/40 85/50 (3) II/4
#2/17/f CBZ,VPA,C 52 3882 65/40 85/45 (6) IV/4
LZ
#3/12/f CBZ,VPA,O 56 4595 65/25 75/45 (4) IV/4
XC
#4/14/f OXC,VPA,G 21 1115 40/30 85/70 (6) II/4
BP
#5/11/f CBZ,OXC,V 51 2207 65/50 80/55 (17) IV/4
PA
#6/15/f ACTH,VPA, 45 2368 40/30 80/40 (3) V/4
LTG,FEN
#7/14/m DHP,VPA 54 1352 40/30 70/50 (48) IV/4
CBZ,OXC,
LTG, DZB
m = male; f = female; CBZ = carbamazepine; OXC = oxcarbazepine; VPA = valproate; LTG = lamotrigine; FEN = felbamate,
GBP = gabapentin; DHP = diphenylhydantoin; DZB = diazepam.
CASE REPORTS
The patients were identifie from the database of
91 patients collected for a national survey of VGB-
associated visual fiel defects in Finnish paediatric
patients with epilepsy (Vanhatalo et al., submitted).
These patients were selected for the present report
due to their exceptional improvement in successive
visual fiel test sessions (Fig. 1), and they thus do
not represent the whole group of Finnish VGB-treated
patients with VFC. The patients were from f ve dif-
ferent hospital districts, and all of their examinations
were performed in their own medical centres. The chil-
dren ranged in age from 10 to 17 years, two were
males and f ve were females, aetiology of the epilepsy
was unknown in six patients. Neuroradiology was nor-
mal in four patients (#2, 4, 5, 7). One patient had
venous angioma in the right frontal lobe (#1), one
had hypovermis, megacisterna magna and an enlarged
fourth ventricle (#3), one patient had tuberose sclero-
sis (#6). All patients had used several other antiepilep-
tic drugs (AEDs), and other AEDs were continued af-
ter cessation of their VGB therapy (see Table 1). Five
of the patients had normal intelligence: two patients
(#2 and #6) had low intelligence, but their perfor-
mance in visual fie d testing was assessed as reli-
able.
All patients underwent an ophthalmological exami-
nation: they had normal fundoscopy and visual acuity.
None of the patients had experienced symptoms of vi-
sual fiel narrowing. Peripheral visual field were ex-
amined with a kinetic Goldmann perimeter with stan-
dard objects (see Table 1). Since the children were
tested in their own medical center, the stimuli in the
perimetry tests differed somewhat. However, we be-
lieve that this slight variation in stimuli used does not
effect the main findin in our study, because all the
patients were successively tested in the same place, i.e.
in his/her own medical center. All patient records and
visual fiel charts were re-analysed by the same oph-
thalmologist (I.N.). Patient #3 was the other patient in
our previous case report3.
DISCUSSION
VFC associated with VGB is a serious side effect,
which increases reluctance to prescribe VGB in paedi-
atric patients: appearance of VFC often results in with-
drawal of the drug. In many countries VGB is still an
add-on or second-line therapy, and reluctance to use
it, due to suspected VFC, may result in difficultie in
findin other appropriate medication. Thus, both ex-
hibiting and withdrawing VGB should always be care-
fully considered.
Recently, some improvement in visual fiel defects
have been reported in single young patients5, 8, 10, 11.
These reports raise the question whether retinal func-
tion might show some recovery in young people, de-
spite apparently permanent damage to retinal cells.
The mechanism of VFC still remains unknown. Re-
cent studies suggest that VGB causes a general defect
in the retinal network rather than outer retinal dam-
age only13, 14. Theoretically such a defect might func-
tionally recover, at least to some extent, in younger
people whose neural systems still possess significan
plasticity. However, reliable testing of the visual field
requires good collaboration, attention and intellectual
abilities. Especially in paediatric patients all of these
factors are highly variable. Children show a wide
range of normal visual fiel values as compared to
adults, and a marked enlargement of the visual field
Reversed VFC in children after vigabatrin withdrawal 511
during development7. Also, repeated visual fiel ex-
amination often gives a better result due to a learning
effect, which may account for some of the observed
improvement in our patients. Retrospectively assessed,
it may also be possible that a psychogenic visual fiel
narrowing, (the ‘amblyopic school girl syndrome’15)
partly explains poor performance during the worst test
sessions. There are, however, some finding suggest-
ing a true visual fiel recovery: collaboration and con-
centration on the test was judged to be reliable dur-
ing all test sessions, three of the patients had previ-
ously given better results, and the improvement of the
visual fiel results was seen after cessation of the ther-
apy. Two of the patients (#6 and #7) also showed nar-
rowing of the visual fields assessed by finge perime-
try, at the time of the worst Goldmann perimetry
results. Thus, the possibility of a true visual fiel re-
covery after VGB withdrawal cannot be excluded, al-
though our present retrospective data cannot confir
it.
The therapeutic paradigms, e.g. drug doses and du-
ration of the therapy, differ markedly between children
and adults. The maturing nervous system also pos-
sesses a high potential for plasticity. Thus it is possible
that the characteristics of VGB-associated VFC may
differ between children and adults. Preliminary analy-
sis of the Finnish national survey on VGB-associated
visual fiel defects in children suggests a much lower
incidence of VFC in children than in adults (Vanhat-
alo et al., submitted). Our present cases emphasize that
a safe continuation of VGB therapy and a proper un-
derstanding of VGB-associated VFC require attempts
to reliably demonstrate both the presence and the ab-
sence of VFC in children.
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